GemCyclo Bio is an early-stage bio-pharmaceutical company holding a library of novel orally available cyclic peptides targeting validated molecular pathways of immune and inflammatory diseases (I&I), Cancer, and metabolic diseases.
The innovative new drugs are licensed from the Hebrew University of Jerusalem and designed and synthesized by Prof Chaim Gilon and his colleagues with the proprietary Cycloscan technology, rapidly achieving orally available small cyclic peptides which are highly potent and metabolically stable, enabling multiple routes of administration.
The novel GemCyclo Bio cyclic peptides embrace the best of small molecules and of larger protein drugs; they are easy to synthesize and of low immunogenicity as small molecules, and of highest affinity and selectivity to target active site as monoclonal antibodies (mAbs), and low off-target toxicity, all at the same time in one novel cyclic peptide molecule.
